Table 1.
Calculation of Number of events prevented in the population (NEPP). Number in the population is 31600, and adherence with therapy 78% in each group.
| Outcome achieved | Prevalence of the disease in the population (Pd) | Proportion eligible for treatment (Pe) | Number given treatment | Risk of event of interest in the untreated group (ru) | Relative Risk Reduction (95% CI) | Number of events prevented in the population** (95% CI) |
| Cognitive enhancers to all eligible with compliance taken into account | ||||||
| No deterioration* | 0.03 | 0.55 | 406 | 0.577 | 0.527 (0.321, 0.671) | 123.6 (82.3, 169.1) |
| 4 point improvement* | 0.03 | 0.55 | 406 | 0.268 | 0.151 (0.01, 0.272) | 16.4 (2.1, 31.2) |
| 7 point improvement* | 0.03 | 0.55 | 406 | 0.078 | 0.082 (0.004, 0.154) | 2.6 (0.2, 5.8) |
| Cognitive enhancers to those eligible but not currently treated | ||||||
| No deterioration* | 0.03 | 0.253 | 187 | 0.577 | 0.527 (0.321, 0.671) | 66.8 (44.0, 92.6) |
| 4 point improvement* | 0.03 | 0.253 | 187 | 0.268 | 0.151 (0.01, 0.272) | 8.9 (1.2, 16.8) |
| 7 point improvement* | 0.03 | 0.253 | 187 | 0.078 | 0.082 (0.004, 0.154) | 1.4 (0.11, 3.2) |
| Treatment of hypertension in the population for those eligible but not currently treated | ||||||
| Development of AD | 0.55 | 0.20 | 2711 | 0.005 | 0.605 (0.229, 0.798) | 8.2 (2.3, 16.8) |
*in ADAS-cog scale
**applies to 6-month outcome for cognitive enhancers and 1-year for hypertension treatment